---
layout: post
title: "港股抗疫概念股暴涨！新冠疫苗密集获批开展临床试验 A股节后跟涨？医药板块配置价值凸显（附股）"
date: 2022-04-04 14:48:07 +0800
categories: emnews
tags: 东财滚动新闻
---
> 港股抗疫概念股暴涨！新冠疫苗密集获批开展临床试验 A股节后跟涨？医药板块配置价值凸显（附股）

<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.09939" data-code="09939|116|5" data-code2="09939|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.09939&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 09939_0" data-code="K 09939|116|5" data-code2="K 09939|116|3|" style="border:#d1d1d1 1px solid;" width="577" height="275" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.06185" data-code="06185|116|5" data-code2="06185|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.06185&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 06185_0" data-code="K 06185|116|5" data-code2="K 06185|116|3|" style="border:#d1d1d1 1px solid;" width="577" height="275" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.01093" data-code="01093|116|5" data-code2="01093|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.01093&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 01093_0" data-code="K 01093|116|5" data-code2="K 01093|116|3|" style="border:#d1d1d1 1px solid;" width="577" height="275" /></a></p><!-- EM_StockImg_End --><p>抗疫概念股集体上涨，截至发稿，<span id="Info.116.09939"><a href="http://quote.eastmoney.com/unify/r/116.09939" class="keytip" data-code="116,09939">开拓药业-B</a></span>大涨超38%，<span id="Info.116.01672"><a href="http://quote.eastmoney.com/unify/r/116.01672" class="keytip" data-code="116,01672">歌礼制药-B</a></span>涨近20%，<span id="Info.116.02196"><a href="http://quote.eastmoney.com/unify/r/116.02196" class="keytip" data-code="116,02196">复星医药</a></span>涨超11%，<span id="Info.116.06618"><a href="http://quote.eastmoney.com/unify/r/116.06618" class="keytip" data-code="116,06618">京东健康</a></span>涨超10%，<span id="Info.116.01833"><a href="http://quote.eastmoney.com/unify/r/116.01833" class="keytip" data-code="116,01833">平安好医生</a></span>涨超9%，<span id="Info.116.01093"><a href="http://quote.eastmoney.com/unify/r/116.01093" class="keytip" data-code="116,01093">石药集团</a></span>涨超6%，<span id="Info.116.06185"><a href="http://quote.eastmoney.com/unify/r/116.06185" class="keytip" data-code="116,06185">康希诺生物-B</a></span>涨超4%。<br /></p><p><strong>消息面上，面对反复的新冠疫情，mRNA疫苗受到了重视。<span web="1" href="http://quote.eastmoney.com/unify/r/116.01093" class="em_stock_key_common" data-code="116,01093">石药集团</span>(01093.HK)、<span id="stock_1.688185"><a href="http://quote.eastmoney.com/unify/r/1.688185" class="keytip" data-code="1,688185">康希诺</a></span><span id="quote_1.688185"></span>(06185.HK)一日内接连<span id="Info.3332"><a href="http://data.eastmoney.com/notices/" class="infokey">公告</a></span>获国家药监局批准临床试验。</strong></p><p>此外， “十四五”医药工业规划出台、相关在研管线不断推进，看好mRNA疫苗及其上游供应链相关产品需求放量。</p><p>“十四五”医药工业发展规划明确指出：紧跟疫苗技术发展趋势，支持建设mRNA疫苗，提高疫苗供应链保障水平。</p><p><strong><span id="Info.116.06178"><a href="http://quote.eastmoney.com/unify/r/116.06178" class="keytip" data-code="116,06178">光大证券</a></span>表示，抗疫主线持续受益，重点关注一季报行情，医药板块估值已进入合理区间，配置价值凸显。</strong>进入年报、一季报披露期，建议重点关注两条主线，首先是高景气度、估值合理板块，包括CXO(重点看好CXO龙头和CDMO企业)、抗疫主线(疫苗/检测/药物/特效药上游产业链等)；其次是低估值、<span id="Info.3321"><a href="http://data.eastmoney.com/bbsj/" class="infokey">业绩</a></span>有望反转板块，包括<span id="bk_90.BK1040"><a href="http://quote.eastmoney.com/unify/r/90.BK1040" class="keytip" data-code="90,BK1040">中药</a></span><span id="bkquote_90.BK1040"></span>、血制品、医疗设备(主要是医疗新基建)等。</p><p><span web="1" href="http://quote.eastmoney.com/unify/r/116.06178" class="em_stock_key_common" data-code="116,06178">光大证券</span>认为未来应当积极把握创新化和国际化方向的投资机会。创新药与疫苗方面，推荐<strong><span id="Info.116.01801"><a href="http://quote.eastmoney.com/unify/r/116.01801" class="keytip" data-code="116,01801">信达生物</a></span>(H)、<span id="stock_1.688331"><a href="http://quote.eastmoney.com/unify/r/1.688331" class="keytip" data-code="1,688331">荣昌生物</a></span><span id="quote_1.688331"></span>(H)</strong>；CXO方面，推荐<strong><span id="Info.116.02269"><a href="http://quote.eastmoney.com/unify/r/116.02269" class="keytip" data-code="116,02269">药明生物</a></span>(H)</strong>、<strong><span id="Info.116.03759"><a href="http://quote.eastmoney.com/unify/r/116.03759" class="keytip" data-code="116,03759">康龙化成</a></span>(A股通)、<span id="stock_0.300725"><a href="http://quote.eastmoney.com/unify/r/0.300725" class="keytip" data-code="0,300725">药石科技</a></span><span id="quote_0.300725"></span>(A股通)</strong>；器械设备与生命科学领域，推荐<strong><span id="stock_0.300760"><a href="http://quote.eastmoney.com/unify/r/0.300760" class="keytip" data-code="0,300760">迈瑞医疗</a></span><span id="quote_0.300760"></span>(A股通)、<span id="Info.116.00853"><a href="http://quote.eastmoney.com/unify/r/116.00853" class="keytip" data-code="116,00853">微创医疗</a></span>(H)、<span id="stock_0.300685"><a href="http://quote.eastmoney.com/unify/r/0.300685" class="keytip" data-code="0,300685">艾德生物</a></span><span id="quote_0.300685"></span>(A股通)</strong>；创新前沿技术方面，关注艾博生物等未上市企业；内需消费方面，推荐<strong><span id="Info.116.01951"><a href="http://quote.eastmoney.com/unify/r/116.01951" class="keytip" data-code="116,01951">锦欣生殖</a></span>(H)、<span id="stock_1.603883"><a href="http://quote.eastmoney.com/unify/r/1.603883" class="keytip" data-code="1,603883">老百姓</a></span><span id="quote_1.603883"></span>(A股通)、<span id="stock_0.000915"><a href="http://quote.eastmoney.com/unify/r/0.000915" class="keytip" data-code="0,000915">华特达因</a></span><span id="quote_0.000915"></span>(A股通)、<span id="stock_0.300294"><a href="http://quote.eastmoney.com/unify/r/0.300294" class="keytip" data-code="0,300294">博雅生物</a></span><span id="quote_0.300294"></span>(A股通)</strong>。<strong>(</strong><a href="https://hk.eastmoney.com/a/202203112306277493.html"><strong>如何利用A股通投资A股市场？</strong></a><strong>)</strong></p><center><img src="https://dfscdn.dfcfw.com/download/D24664021408162271194_w1204h1816.jpg" width="580" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p><strong>相关阅读：</strong></p><p><strong><a href="https://finance.eastmoney.com/a/202204042332446636.html">两公司接连获批mRNA疫苗临床！新疫苗有望更有效应对新冠变异株</a><br /></strong></p><p class="em_media">（文章来源：哈富<span id="bk_90.BK0473"><a href="http://quote.eastmoney.com/unify/r/90.BK0473" class="keytip" data-code="90,BK0473">证券</a></span><span id="bkquote_90.BK0473"></span>）</p>

<http://hk.eastmoney.com/news/11382,202204042332479112.html>

[返回东财滚动新闻](//finews.withounder.com/emnews/)｜[返回首页](//finews.withounder.com/)